Symbols

AZN

Astrazeneca·NYSE

--(--)

AZN fundamentals

AZN Q4 2025 Earnings

Astrazeneca (AZN) released its earnings on Feb 10, 2026: revenue was 15.50B (YoY +4.11%), beat estimates; EPS was 2.12 (YoY +102.87%), beat estimates.

Revenue / YoY

15.50B

+4.11%

EPS / YoY

2.12

+102.87%

Report date

Feb 10, 2026

AZN Earnings Call Summary for Q4,2025

Revenue & Profit Growth: 8% revenue growth in 2025, core EPS up 11%. 2026 guidance for mid- to high-single-digit revenue growth despite headwinds.
Pipeline Strength: 100+ Phase III trials ongoing, with 2026 readouts valued at $10 billion+ peak sales. 16 blockbusters in 2025, targeting 25 by 2030.
China Expansion: Emerging markets growth 4% in 2025, driven by NRDL inclusions and new launches. Managing VBP headwinds while investing in local manufacturing.
Strategic Investments: $80 billion 2030 target supported by R&D in ADCs, cell therapies, and weight management. 2026 CapEx increase for U.S. and China expansion.

Earnings

EPS

Revenue

Revenue & Expenses

AZN has released its 2025 Q4 earnings report, with revenue of 15.50B, reflecting a YoY change of 4.11%, and net profit of 2.33B, showing a YoY change of 55.27%. The Sankey diagram below clearly presents AZN's revenue sources and cost distribution.

Key Indicators

Astrazeneca (AZN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Astrazeneca (AZN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Astrazeneca (AZN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Astrazeneca (AZN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown